Skip to main content
Caplight Logo









GentiBio

GentiBio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.gentibio.com/

Last Round

Series A

Aug 11, 2021

Total Funding Raised

$177M

Company Overview

GentiBio is a biotechnology company that develops engineered regulatory T-cell (EngTreg) therapies to restore immune tolerance and treat autoimmune, alloimmune, autoinflammatory, and allergic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regulatory T cellTregcell therapyengineered cell therapyimmune toleranceautoimmune disease treatmentbiotechnext-gen cell therapyantigen-specific Tregbiopharmaceutical partnershipautologous therapyallogeneic therapysynthetic biologydrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GentiBio Comparables

Compare GentiBio with similar companies based on industry and business-model similarity.

GentiBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Quell Therapeutics
87%
Sonoma Biotherapeutics
86%
Mozart Therapeutics
86%

GentiBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 11, 2021
SeedAug 5, 2020

Key People

Founding team and executive leadership

Andy Walker

Co-founder, President and Chief Executive Officer (CEO)

Founding Team

GentiBio Investors

Notable investors and investment history

GentiBio investors
InvestorRounds
RA Capital ManagementSeries A, Seed
Avidity PartnersSeries A
OrbiMedSeries A, Seed
Matrix Capital ManagementSeries A
JDRFSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 2, 2026

    Will present new data on engineered Treg therapy at the PES Annual Meeting.

  • Apr 29, 2026

    New data on GNTI-122 Treg therapy to be presented at medical conference.

GentiBio Filings

Explore SEC and related filing metadata, where available.

GentiBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about GentiBio's valuation, stock price, and market status.

Is GentiBio a public or private company?

GentiBio is a private company.

What is the current stock price of GentiBio?

GentiBio is a private company with no public stock price. No recent secondary market data is available.

How much is GentiBio worth (valuation)?

Valuation information for GentiBio is not publicly available.

Can I buy GentiBio stock?

GentiBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was GentiBio's last funding round?

GentiBio's most recent funding round was Series A on August 11, 2021.

Who are the main investors in GentiBio?

Key investors in GentiBio include RA Capital Management, OrbiMed, Matrix Capital Management.

Will GentiBio IPO soon?

No public IPO plans have been announced for GentiBio.

How can I track GentiBio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GentiBio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range43
Year Founded2020
Last FundingAug 11, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?